Over on VentureBeat, David Hamilton writes that even normally smart biotechnology investors get a little dim when talking about biosimilars and the loss of patent protection for biotech drugs. Steve Burrill, CEO of the life science venture capital firm Burrill & Company, told Fortune magazine that the approval of biosimilars will be "devastating for the industry." Hamilton responds that "if the biotech industry is so delicate that it requires perpetual protection from the cold, cruel winds of competition, it can’t possibly be anywhere near as innovative and revolutionary as it has always claimed."